• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "Suppression of abdominal fat and anti-hyperlipidemic potential of Emblica officinalis: Upregulation of PPARs and identification of active moiety" Biomed. Pharmacother. 108 (2018) 1274-1281.

作者信息

Variya Bhavesh C, Bakrania Anita K, Chen Yuanli, Han Jihong, Patel Snehal S

机构信息

Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India.

Collaborative Innovation Center of Biotherapy, School of Medicine, Nankai University, Tianjin 300071, China.

出版信息

Biomed Pharmacother. 2024 Aug;177:116945. doi: 10.1016/j.biopha.2024.116945. Epub 2024 Jun 19.

DOI:10.1016/j.biopha.2024.116945
PMID:38897910
Abstract
摘要

相似文献

1
Corrigendum to "Suppression of abdominal fat and anti-hyperlipidemic potential of Emblica officinalis: Upregulation of PPARs and identification of active moiety" Biomed. Pharmacother. 108 (2018) 1274-1281.《余甘子抑制腹部脂肪和抗高血脂的潜力：过氧化物酶体增殖物激活受体的上调及活性成分鉴定》的勘误，发表于《生物医学与药物治疗》108卷（2018年）第1274 - 1281页。
Biomed Pharmacother. 2024 Aug;177:116945. doi: 10.1016/j.biopha.2024.116945. Epub 2024 Jun 19.
2
Suppression of abdominal fat and anti-hyperlipidemic potential of Emblica officinalis: Upregulation of PPARs and identification of active moiety.余甘子对腹部脂肪的抑制作用及其抗高血脂潜力：PPARs 的上调和活性成分的鉴定。
Biomed Pharmacother. 2018 Dec;108:1274-1281. doi: 10.1016/j.biopha.2018.09.158. Epub 2018 Oct 3.
3
(Amla) Ameliorates High-Fat Diet Induced Alteration of Cardiovascular Pathophysiology.（印度醋栗）改善高脂饮食诱导的心血管病理生理学改变。
Cardiovasc Hematol Agents Med Chem. 2019;17(1):52-63. doi: 10.2174/1871525717666190409120018.
4
Corrigendum to "Bixin ameliorates high fat diet-induced cardiac injury in mice through inflammation and oxidative stress suppression" [Biomed. Pharmacother. 89;991-1004(2017)].《关于“紫胶红素通过抑制炎症和氧化应激改善高脂饮食诱导的小鼠心脏损伤”的勘误》[《生物医学与药物治疗》89卷；991 - 1004页(2017年)]
Biomed Pharmacother. 2024 Jul;176:116795. doi: 10.1016/j.biopha.2024.116795. Epub 2024 Jun 8.
5
Attenuation of Hyperlipidemia by Medicinal Formulations of Synergized with Nanotechnological Approaches.通过与纳米技术方法协同的药用制剂减轻高脂血症
Bioengineering (Basel). 2023 Jan 4;10(1):64. doi: 10.3390/bioengineering10010064.
6
Corrigendum to "Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1" [Biomed. Pharmacother. 106 (2018) 1390-1395].《阿托伐他汀对心肌的抗肥厚作用取决于通过Foxo1激活AMPK诱导的miR-143-3p抑制》的勘误[《生物医学与药物治疗》106(2018)1390 - 1395]
Biomed Pharmacother. 2024 Feb;171:116141. doi: 10.1016/j.biopha.2024.116141. Epub 2024 Jan 12.
7
Corrigendum to "Qiangguyin inhibited fat accumulation in OVX mice through the p38 MAPK signaling pathway to achieve anti-osteoporosis effects"[Biomed. Pharmacother. 158 (2023) 114122].《强骨饮通过p38丝裂原活化蛋白激酶信号通路抑制去卵巢小鼠脂肪堆积以实现抗骨质疏松作用》的勘误[《生物医学与药物治疗》158 (2023) 114122]
Biomed Pharmacother. 2024 Jul;176:116914. doi: 10.1016/j.biopha.2024.116914. Epub 2024 Jun 8.
8
Retraction notice to "Corrigendum to 'mPEG-b-P(Glu-co-Phe) nanoparticles increase gastric retention time and gastric ulcer treatment efficacy of 20(S)-ginsenoside Rg3' [Biomed. Pharmacother. 146 (2022) 112608]" [Biomed. Pharmacother. 152 (2022) 113213].对“《‘mPEG-b-P(Glu-co-Phe)纳米颗粒增加20(S)-人参皂苷Rg3的胃滞留时间和胃溃疡治疗效果’的勘误》[生物医学与药物治疗学146 (2022) 112608]”[生物医学与药物治疗学152 (2022) 113213]的撤回通知。
Biomed Pharmacother. 2023 Apr;160:114280. doi: 10.1016/j.biopha.2023.114280. Epub 2023 Jan 31.
9
Corrigendum to "Chlorogenic acid attenuates glucotoxicity in H9c2 cells via inhibition of glycation and PKC α upregulation and safeguarding innate antioxidant status" [Biomed. Pharmacother. 100 (2018) 467-477].《绿原酸通过抑制糖基化、上调蛋白激酶Cα以及维持固有抗氧化状态减轻H9c2细胞中的糖毒性》[《生物医学与药物治疗》100 (2018) 467 - 477]的勘误
Biomed Pharmacother. 2021 Jan;133:111071. doi: 10.1016/j.biopha.2020.111071. Epub 2020 Dec 6.
10
Emblica officinalis - Anti-obesity activity.余甘子 - 抗肥胖活性。
J Complement Integr Med. 2017 Dec 5;15(2):/j/jcim.2018.15.issue-2/jcim-2016-0051/jcim-2016-0051.xml. doi: 10.1515/jcim-2016-0051.